tbc-11251 has been researched along with Hyperuricemia in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dhaun, N; Goddard, J; Johnston, NR; Webb, DJ | 1 |
1 trial(s) available for tbc-11251 and Hyperuricemia
| Article | Year |
|---|---|
Chronic selective endothelin A receptor antagonism reduces serum uric acid in hypertensive chronic kidney disease.
Topics: Cross-Over Studies; Double-Blind Method; Endothelin A Receptor Antagonists; Hypertension; Hyperuricemia; Isoxazoles; Kidney Failure, Chronic; Thiophenes; Treatment Outcome; Uric Acid | 2011 |